Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population

BACKGROUND: Trastuzumab emtansine (T-DM1) has been approved since 2013 for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who had received trastuzumab (Tmab) and taxane. However, no clinical trial has evaluated the efficacy of T-DM1 in those who...

Descripción completa

Detalles Bibliográficos
Autores principales: Noda-Narita, Shoko, Shimomura, Akihiko, Kawachi, Asuka, Sumiyoshi-Okuma, Hitomi, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Yonemori, Kan, Shimizu, Chikako, Fujiwara, Yasuhiro, Tamura, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570684/
https://www.ncbi.nlm.nih.gov/pubmed/30737616
http://dx.doi.org/10.1007/s12282-019-00949-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570684/
https://www.ncbi.nlm.nih.gov/pubmed/30737616
http://dx.doi.org/10.1007/s12282-019-00949-4

Ejemplares similares